GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Price-to-Owner-Earnings

Panbela Therapeutics (Panbela Therapeutics) Price-to-Owner-Earnings : (As of Jun. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-02), Panbela Therapeutics's share price is $0.40. Panbela Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Panbela Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


PBLA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-02), Panbela Therapeutics's share price is $0.40. Panbela Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-228.57. Therefore, Panbela Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-02), Panbela Therapeutics's share price is $0.40. Panbela Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-231.31. Therefore, Panbela Therapeutics's PE Ratio without NRI for today is At Loss.


Panbela Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Panbela Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panbela Therapeutics Price-to-Owner-Earnings Chart

Panbela Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Panbela Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Panbela Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Panbela Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panbela Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Price-to-Owner-Earnings falls into.



Panbela Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Panbela Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.40/-243.76
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panbela Therapeutics  (OTCPK:PBLA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Panbela Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Panbela Therapeutics (Panbela Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Executives
Jennifer K. Simpson director, officer: President and CEO C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath officer: V.P. of Finance & CFO 4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob director 712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer director 712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust 10 percent owner 1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson 10 percent owner 130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel director 712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill director 712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen officer: Chief Financial Officer 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen director 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr director
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen director 712 VISTA BLVD, #305, WACONIA MN 55387

Panbela Therapeutics (Panbela Therapeutics) Headlines

From GuruFocus

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

By Stock market mentor Stock market mentor 01-12-2023